Natera (NTRA) Stock Price, Quote, News & History | Benzinga

Natera Inc (NTRA) Stock Price, Quote, News & History

NTRANASDAQ

Trade with Public

Trade with Public

$320.70

-1.40-0.43%

Last update: Aug 10, 2:56 PM

Earnings: Q2 2026 Earnings were released on Thu Aug 6th, after the market close

Conference Call: The most recent conference call started at 4:30 PM, 4 days ago

Click to view the webcast

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$321.59

Close

-

Volume / Avg.

1.54M / 1.53M

Day Range

$310.95 - $326.03

52 Wk Range

136.21 - 323.01

Market Cap

$46.23B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

74

Short Interest

3.55%

Days to Cover

3.61

Recent Natera, Inc. News

Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday

U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 results and raised FY26 sales guidance. Other big gains include DOCS, QNST, TEAM, CRSR, OABI, PUBM, TWLO, BTG, and ROAD.

Avi Kapoor

Natera CEO Says Company Is 'Clearly on a Roll' After Record Test Volumes, Raises Outlook

Natera stock spikes as strong oncology demand drives record test volumes and a full-year revenue outlook bump.

Vandana Singh

S&P 500 Hits Record As Jobs Shock Sinks Rate-Hike Bets: Stock Market Today

U.S. payrolls fell 23,000 in July, gutting September Fed hike odds. The S&P 500 hit a record, while gold jumped to a seven-week high.

Piero Cingari

Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring

Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.

Vandana Singh

Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer

Natera won Japan approval for Signatera in colorectal cancer, paving the way for a commercial launch by 2026.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

228.24M

Investing Cash Flow (TTM)

-187.06M

Financing Cash Flow (TTM)

50.31M

Free Cash Flow (TTM)

51.20M

Capital Expenditure (TTM)

-177.04M

Net Change in Cash (TTM)

91.48M

Analyst Trends and Forecast

1

Apr

3

1

May

7

1

Jun

3

Jul

6

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$45.58B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

16.67

PB Ratio (TTM)

25.49

Earnings Yield % (TTM)

-0.42%

Earnings Yield % (FWD)

-0.53%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

881.44

Book Value / Share

$12.64

Company Debt

Total Debt

$80.29M

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$1.09B

Debt to Equity

0.13

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$321.59

Close

-

Volume / Avg.

1.54M / 1.53M

Day Range

$310.95 - $326.03

52 Wk Range

136.21 - 323.01

Market Cap

$46.23B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

74

Short Interest

3.55%

Days to Cover

3.61

About

Sector

Health Care

Industry

Biotechnology

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetu...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Natera (NTRA) stock?

A

You can purchase shares of Natera (NASDAQ:NTRA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Natera (NTRA) competitors?

A

Other companies in Natera’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Natera (NTRA) stock?

A

Natera has a consensus price target of $267.31.

Q

What is the current price for Natera (NTRA)?

A

The stock price for Natera (NASDAQ: NTRA) is $320.705 last updated August 10, 2026 at 2:56 PM EDT.

Q

Does Natera (NTRA) pay a dividend?

A

There are no upcoming dividends for Natera.

Q

When is Natera (NASDAQ:NTRA) reporting earnings?

A

Natera does not have any upcoming earnings scheduled.

Q

Is Natera (NTRA) going to split?

A

There is no upcoming split for Natera.

Q

What sector and industry does Natera (NTRA) operate in?

A

Natera is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.